MedTrace Logo

Omics Signature in the Diagnosis of Hypertension

NCT02772315 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2017-01-26

No results posted yet for this study

Summary

The purpose of this study is to assess the validity and usefulness of omics signatures for improved identification and risk stratification of patients with endocrine hypertension and stratification of patients with primary hypertension.

Conditions

Interventions

OTHER

omics

diagnostic procedures applying omics results

Sponsors & Collaborators

  • European Georges Pompidou Hospital

    collaborator OTHER

  • University of Turin, Italy

    collaborator OTHER

  • University of Padova

    collaborator OTHER

  • University of Glasgow

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Maria Christina Zennaro, PhD · AP/HECP, Paris

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-05-31
Completion
2019-05-31

Countries

  • France
  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02772315 on ClinicalTrials.gov